New KRAS Drug Daraxonrasib Nearly Doubles Survival in Pancreatic Cancer Trial

Pancreatic cancer carries one of the worst prognoses of any malignancy, largely due to the high prevalence of KRAS mutations in tumor cells. KRAS, the most commonly mutated oncogene in pancreatic cancer, was for decades considered impossible to target because of its smooth, featureless protein surface, leaving patients with few effective options after first-line treatment fails.

Daraxonrasib, developed by Revolution Medicines and recently approved by the FDA, represents a genuine scientific breakthrough. It is the first drug proven to bind, inhibit, and block KRAS activity inside pancreatic tumors. In the pivotal clinical trial conducted in previously treated patients, the drug nearly doubled survival rates — a remarkable achievement given how resistant this cancer has historically been to intervention.

The broader argument of this opinion piece is that breakthroughs like daraxonrasib don't emerge from thin air. They are the product of decades of federally funded basic research — research that mapped KRAS's structure, identified its role in cancer biology, and laid the molecular groundwork that private companies could eventually build upon. The author contends that the NIH's current budget is insufficient to sustain this pipeline of discovery at the scale needed.

The piece calls for a dramatic increase in NIH funding — to $100 billion per year — arguing that such investment would accelerate the pace of transformative therapies across cancer and other age-related diseases. The daraxonrasib story is presented as proof of concept: long-term public funding of seemingly intractable scientific problems eventually yields life-saving results.

For readers focused on longevity and healthspan, this matters because pancreatic cancer remains one of the leading causes of cancer mortality in older adults, and KRAS-targeted therapies could eventually extend to other KRAS-driven cancers including lung and colorectal tumors.